DYN Dyne Therapeutics, Inc.
Nasdaq · SEC CIK 1818794 · EDGAR
- Bought, last 12 months
- $274.8K 7 purchases by 1 insiders
- Sold, last 12 months
- $168.62M 38 sales by 6 insiders
- Filings on record
- 301 since 2021-07-13, latest 2026-09-08 16:15
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Rhodes Jason P | Dir | — | $129.10M |
| Kersten Dirk | Dir | — | $38.57M |
| Cox John | CEO, Pres, Dir | — | $443.7K |
| Posner Brian S | Dir | $274.8K | — |
| Kerr Douglas | Chief Medical Off | — | $233.1K |
| Lucera Erick | CFO | — | $228.7K |
| Friedl-Naderer Johanna | Chief Commercial Off | — | $43.4K |
| Lubner David Charles | Dir | — | — |
Transactions 289
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-10 | 2024-09-06 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | M - OptEx | $12.56 | +116.5K | 117.5K | +11,136% | +$1.46M |
| DM | 2024-09-10 | 2024-09-06 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale+OE | $32.15 | -126.1K | 103.1K | -55% | -$4.05M |
| TI | 2024-09-09 | 2024-09-05 | DYN | Kersten Dirk | Dir | S - Sale | $35.03 | -1,577 | 398.4K | -0.4% | -$55.2K |
| MI | 2024-09-04 | 2024-09-04 | DYN | Cox John | CEO, Pres, Dir | P - Purchase | $33.04 | +32.0K | 800 | New | +$1.06M |
| MTI | 2024-09-04 | 2024-08-30 | DYN | Kersten Dirk | Dir | S - Sale | $45.59 | -31.3K | 400.0K | -7% | -$1.43M |
| D | 2024-09-03 | 2024-09-03 | DYN | Friedl-Naderer Johanna | Chief Commercial Off | A - Grant | $0.00 | +58.4K | 58.4K | New | $0 |
| D | 2024-09-03 | 2024-09-03 | DYN | Kerr Douglas | Chief Medical Off | A - Grant | $0.00 | +47.5K | 47.5K | New | $0 |
| MTI | 2024-08-30 | 2024-08-28+ | DYN | Kersten Dirk | Dir | S - Sale | $45.03 | -134.3K | 431.3K | -24% | -$6.05M |
| MTI | 2024-08-28 | 2024-08-26+ | DYN | Kersten Dirk | Dir | S - Sale | $44.87 | -154.9K | 631.0K | -20% | -$6.95M |
| MTI | 2024-08-26 | 2024-08-22+ | DYN | Kersten Dirk | Dir | S - Sale | $46.02 | -180.4K | 805.5K | -18% | -$8.30M |
| MTI | 2024-08-22 | 2024-08-20+ | DYN | Kersten Dirk | Dir | S - Sale | $46.61 | -222.6K | 1.04M | -18% | -$10.38M |
| MT | 2024-08-20 | 2024-08-19 | DYN | HIGH SUSANNA GATTI | COO | S - Sale | $45.12 | -2,910 | 145.9K | -2% | -$131.3K |
| MT | 2024-08-20 | 2024-08-19 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $45.12 | -2,321 | 143.5K | -2% | -$104.7K |
| MT | 2024-08-20 | 2024-08-19 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale | $45.12 | -2,752 | 111.3K | -2% | -$124.2K |
| MT | 2024-08-20 | 2024-08-19 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $45.12 | -2,636 | 144.9K | -2% | -$118.9K |
| MTI | 2024-08-20 | 2024-08-16+ | DYN | Kersten Dirk | Dir | S - Sale | $45.48 | -248.7K | 1.13M | -18% | -$11.31M |
| MT | 2024-08-20 | 2024-08-19 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $45.12 | -2,705 | 132.4K | -2% | -$122.1K |
| MTI | 2024-08-16 | 2024-08-14+ | DYN | Kersten Dirk | Dir | S - Sale | $44.76 | -281.5K | 1.55M | -15% | -$12.60M |
| MATI | 2024-08-14 | 2024-08-08+ | DYN | Kersten Dirk | Dir | S - Sale | $42.85 | -183.8K | 1.91M | -9% | -$7.88M |
| MTI | 2024-08-14 | 2024-08-12+ | DYN | Kersten Dirk | Dir | S - Sale | $42.93 | -212.5K | 1.65M | -11% | -$9.12M |
| MTI | 2024-08-12 | 2024-08-08+ | DYN | Kersten Dirk | Dir | S - Sale | $42.85 | -183.8K | 6.23M | -3% | -$7.88M |
| DMAT | 2024-07-03 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $5.54 | +40.0K | 178.6K | +29% | +$221.6K |
| DMAT | 2024-07-03 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | S - Sale+OE | $35.09 | -40.0K | 148.8K | -21% | -$1.40M |
| DMT | 2024-06-24 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $5.54 | +40.0K | 159.0K | +34% | +$221.3K |
| DMT | 2024-06-24 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | S - Sale+OE | $35.09 | -40.0K | 148.8K | -21% | -$1.40M |
| DT | 2024-06-13 | 2024-06-12 | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $5.54 | +40.0K | 188.8K | +27% | +$221.6K |
| DMT | 2024-06-13 | 2024-06-12 | DYN | HIGH SUSANNA GATTI | COO | S - Sale+OE | $33.36 | -40.0K | 148.8K | -21% | -$1.33M |
| 2024-06-11 | 2024-06-11 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $31.34 | -1,823 | 134.8K | -1% | -$57.1K | |
| DMT | 2024-06-11 | 2024-06-10+ | DYN | HIGH SUSANNA GATTI | COO | S - Sale+OE | $30.30 | -85.3K | 154.1K | -36% | -$2.58M |
| DT | 2024-06-11 | 2024-06-10 | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $5.54 | +80.0K | 234.1K | +52% | +$443.2K |
| 2024-06-11 | 2024-06-11 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $31.34 | -2,136 | 147.5K | -1% | -$66.9K | |
| MT | 2024-06-11 | 2024-06-11 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $31.27 | -2,636 | 146.6K | -2% | -$82.4K |
| MT | 2024-06-11 | 2024-06-10+ | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale | $30.74 | -2,921 | 115.1K | -2% | -$89.8K |
| DMT | 2024-05-22 | 2024-05-20 | DYN | Beskrovnaya Oxana | CSO | S - Sale+OE | $32.96 | -30.4K | 149.6K | -17% | -$1.00M |
| DT | 2024-05-22 | 2024-05-20 | DYN | Beskrovnaya Oxana | CSO | M - OptEx | $1.03 | +30.4K | 180.1K | +20% | +$31.3K |
| MT | 2024-05-17 | 2024-05-16 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale | $28.27 | -2,588 | 116.7K | -2% | -$73.2K |
| MT | 2024-05-17 | 2024-05-16 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $28.27 | -2,381 | 148.2K | -2% | -$67.3K |
| MT | 2024-05-17 | 2024-05-16 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $28.27 | -2,774 | 137.1K | -2% | -$78.4K |
| MT | 2024-05-17 | 2024-05-16 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $28.27 | -2,705 | 150.1K | -2% | -$76.5K |
| MT | 2024-05-17 | 2024-05-16 | DYN | HIGH SUSANNA GATTI | COO | S - Sale | $28.27 | -2,738 | 154.6K | -2% | -$77.4K |
| DMT | 2024-03-13 | 2024-03-08+ | DYN | McNeill Jonathan | Chief Business Off | S - Sale+OE | $26.11 | -109.6K | 141.9K | -44% | -$2.86M |
| DMT | 2024-03-13 | 2024-03-08+ | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $5.54 | +107.8K | 227.3K | +90% | +$597.4K |
| MT | 2024-03-13 | 2024-03-08+ | DYN | HIGH SUSANNA GATTI | COO | S - Sale | $26.59 | -29.5K | 159.1K | -16% | -$784.2K |
| MT | 2024-03-12 | 2024-03-11+ | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $25.65 | -2,615 | 151.6K | -2% | -$67.1K |
| T | 2024-03-12 | 2024-03-11 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $25.70 | -2,081 | 152.4K | -1% | -$53.5K |
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Brumm Joshua T | CEO, Pres, Dir | M - OptEx | $5.54 | +413.3K | 604.4K | +216% | +$2.29M |
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Brumm Joshua T | CEO, Pres, Dir | S - Sale+OE | $25.89 | -429.7K | 554.4K | -44% | -$11.13M |
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale+OE | $26.19 | -88.9K | 119.3K | -43% | -$2.33M |
| DMT | 2024-03-12 | 2024-03-08 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | M - OptEx | $5.54 | +86.3K | 190.9K | +82% | +$477.8K |
| MT | 2024-03-11 | 2024-03-07 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $25.86 | -9,921 | 154.7K | -6% | -$256.6K |
| T | 2024-03-11 | 2024-03-07 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale | $25.85 | -2,273 | 122.0K | -2% | -$58.8K |
| T | 2024-03-11 | 2024-03-07 | DYN | Brumm Joshua T | CEO, Pres, Dir | S - Sale | $25.85 | -9,086 | 554.4K | -2% | -$234.9K |
| T | 2024-03-11 | 2024-03-07 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $25.85 | -2,373 | 154.4K | -2% | -$61.3K |
| T | 2024-03-11 | 2024-03-07 | DYN | HIGH SUSANNA GATTI | COO | S - Sale | $25.85 | -1,591 | 186.3K | -0.8% | -$41.1K |
| T | 2024-03-11 | 2024-03-07 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $25.85 | -2,434 | 141.2K | -2% | -$62.9K |
| I | 2024-03-05 | 2024-03-01 | DYN | Atlas Venture Associates Opportunity II, LP | 10% | S - Sale | $30.05 | -17.1K | 847.4K | -2% | -$513.8K |
| 2024-03-05 | 2024-03-01 | DYN | Atlas Venture Associates Opportunity II, LP | 10% | S - Sale | $30.05 | -29.4K | 1.46M | -2% | -$884.5K | |
| MI | 2024-03-05 | 2024-03-01 | DYN | Rhodes Jason P | Dir | S - Sale | $30.05 | -46.5K | 1.46M | -3% | -$1.40M |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +28.5K | 167.9K | +20% | +$20.8K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | McNeill Jonathan | Chief Business Off | S - Sale+OE | $28.46 | -28.5K | 143.6K | -17% | -$811.9K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Brumm Joshua T | CEO, Pres, Dir | S - Sale+OE | $28.96 | -100.0K | 563.5K | -15% | -$2.90M |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Brumm Joshua T | CEO, Pres, Dir | M - OptEx | $5.54 | +100.0K | 569.0K | +21% | +$554.0K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | M - OptEx | $1.03 | +12.7K | 133.5K | +11% | +$13.1K |
| DMT | 2024-03-01 | 2024-02-29+ | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale+OE | $28.05 | -12.7K | 124.8K | -9% | -$357.3K |
| MI | 2024-02-28 | 2024-02-26+ | DYN | Atlas Venture Associates XI, L.P. | 10% | S - Sale | $24.30 | -153.4K | 1.51M | -9% | -$3.73M |
| M | 2024-02-28 | 2024-02-26+ | DYN | Atlas Venture Associates XI, L.P. | 10% | S - Sale | $24.30 | -654.5K | 6.22M | -10% | -$15.90M |
| MI | 2024-02-28 | 2024-02-26+ | DYN | Rhodes Jason P | Dir | S - Sale | $24.30 | -807.8K | 880.0K | -48% | -$19.63M |
| T | 2024-02-28 | 2024-02-28 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $25.00 | -407 | 163.1K | -0.2% | -$10.2K |
| M | 2024-02-23 | 2024-02-21+ | DYN | Atlas Venture Associates XI, LLC | 10% | S - Sale | $22.64 | -463.4K | 6.51M | -7% | -$10.49M |
| MI | 2024-02-23 | 2024-02-23 | DYN | Atlas Venture Associates XI, LLC | 10% | S - Sale | $22.70 | -37.4K | 1.59M | -2% | -$848.7K |
| MI | 2024-02-23 | 2024-02-21+ | DYN | Rhodes Jason P | Dir | S - Sale | $22.64 | -500.8K | 6.35M | -7% | -$11.34M |
| M | 2024-02-20 | 2024-02-15+ | DYN | Atlas Venture Associates XI, L.P. | 10% | S - Sale | $23.26 | -510.2K | 6.82M | -7% | -$11.87M |
| MI | 2024-02-20 | 2024-02-15+ | DYN | Rhodes Jason P | Dir | S - Sale | $23.26 | -510.2K | 7.15M | -7% | -$11.87M |
| T | 2024-02-14 | 2024-02-12 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $25.07 | -5,493 | 163.5K | -3% | -$137.7K |
| M | 2024-01-31 | 2024-01-29 | DYN | Brumm Joshua T | CEO, Pres, Dir | G - Gift | $0.00 | -21.5K | 563.5K | -4% | $0 |
| DT | 2024-01-26 | 2024-01-26 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale+OE | $24.34 | -13.0K | 124.2K | -9% | -$316.4K |
| DT | 2024-01-26 | 2024-01-26 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | M - OptEx | $1.03 | +13.0K | 137.2K | +10% | +$13.4K |
| T | 2024-01-26 | 2024-01-26 | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $25.00 | -100 | 169.0K | -0.1% | -$2,500 |
| DT | 2024-01-26 | 2024-01-26 | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +20.0K | 163.6K | +14% | +$14.6K |
| DMT | 2024-01-26 | 2024-01-26 | DYN | McNeill Jonathan | Chief Business Off | S - Sale+OE | $24.53 | -20.0K | 143.8K | -12% | -$490.5K |
| MI | 2024-01-11 | 2024-01-09 | DYN | Kersten Dirk | Dir, 10% | P - Purchase | $17.50 | +1.71M | 6.42M | +36% | +$30.00M |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Brumm Joshua T | CEO, Pres | M - OptEx | $4.37 | +269.7K | 803.5K | +51% | +$1.18M |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $18.66 | -269.7K | 585.0K | -32% | -$5.03M |
| DT | 2024-01-04 | 2024-01-03 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | M - OptEx | $1.03 | +13.0K | 137.2K | +10% | +$13.4K |
| DT | 2024-01-04 | 2024-01-03 | DYN | Scalzo Richard William | SVP, Head of Fin, Admin | S - Sale+OE | $18.81 | -13.0K | 124.2K | -9% | -$244.5K |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Beskrovnaya Oxana | CSO | M - OptEx | $1.03 | +68.0K | 199.3K | +52% | +$70.0K |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Beskrovnaya Oxana | CSO | S - Sale+OE | $18.57 | -87.8K | 181.9K | -33% | -$1.63M |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +20.0K | 161.6K | +14% | +$14.6K |
| DMT | 2024-01-04 | 2024-01-02+ | DYN | McNeill Jonathan | Chief Business Off | S - Sale+OE | $16.59 | -31.9K | 143.6K | -18% | -$529.2K |
| 2023-12-14 | 2023-12-14 | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.02 | -2,376 | 124.2K | -2% | -$28.6K | |
| M | 2023-12-12 | 2023-12-11+ | DYN | Farwell Wildon | Chief Medical Off | S - Sale | $10.66 | -2,666 | 169.1K | -2% | -$28.4K |
| 2023-12-12 | 2023-12-11 | DYN | Beskrovnaya Oxana | CSO | S - Sale | $10.72 | -1,467 | 176.6K | -0.8% | -$15.7K | |
| 2023-12-12 | 2023-12-11 | DYN | Scalzo Richard William | See Remarks | S - Sale | $10.72 | -1,380 | 126.6K | -1% | -$14.8K | |
| 2023-12-12 | 2023-12-11 | DYN | HIGH SUSANNA GATTI | COO | S - Sale | $10.72 | -1,616 | 187.9K | -0.9% | -$17.3K | |
| 2023-12-12 | 2023-12-11 | DYN | Brumm Joshua T | See Remarks, Dir | S - Sale | $10.72 | -7,585 | 585.0K | -1% | -$81.3K | |
| 2023-12-12 | 2023-12-11 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $10.72 | -1,245 | 155.5K | -0.8% | -$13.3K | |
| M | 2023-12-06 | 2023-12-04+ | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.01 | -2,553 | 128.0K | -2% | -$30.7K |
| D | 2023-11-16 | 2023-11-15 | DYN | McNeill Jonathan | Chief Business Off | A - Grant | $0.00 | +96.2K | 156.8K | +159% | $0 |
| D | 2023-11-16 | 2023-11-15 | DYN | Farwell Wildon | Chief Medical Off | A - Grant | $0.00 | +82.5K | 171.8K | +92% | $0 |
| D | 2023-11-16 | 2023-11-15 | DYN | Scalzo Richard William | See Remarks | A - Grant | $0.00 | +89.7K | 130.5K | +220% | $0 |
Purchase Sale Sale after option exercise All abbreviations